When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Destampasidis requested media coverage of the trial - Maria Marangelis, the former protected witness "Ekaterini Kelesi", is ...

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

Novartis (NYSE:NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

Basel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price ...